★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Elevance Health, Inc.
ELV · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Elevance Health operates Health Benefits, CarelonRx and Carelon Services. Its clearest moat is the Blue Cross Blue Shield license footprint: territory-based rights to use the Blue marks create a legally protected distribution and brand position in multiple states, although exclusivity is not universal. CarelonRx and Carelon Services have modest workflow switching costs where claims, member-service, care-management and utilization processes are integrated, and affiliated plans provide a built-in route for pharmacy bundling. Membership size, government-program exposure and broad service menus were not scored independently because the cited evidence established scale or activity, not lower unit costs, contract incumbency or scope economies. Medical-cost inflation, annual repricing, provider consolidation, competitive government rebids, PBM regulation, RFP churn and buyer unbundling constrain the moat.
Primary segment
Health Benefits
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 8 tags
Updated 2026-07-12
Segments
Health Benefits
U.S. health insurance and managed care
Revenue
84.1%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
CarelonRx
U.S. pharmacy benefit management and pharmacy services
Revenue
12.3%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Carelon Services
U.S. healthcare services for payers and providers (care management, behavioral health, utilization management, care delivery)
Revenue
3.6%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Moat Claims
Health Benefits
U.S. health insurance and managed care
2025 segment unaffiliated operating revenue: $167.094B; operating gain: $4.158B. Revenue_share is normalized to the sum of unaffiliated operating revenues of Health Benefits, CarelonRx, and Carelon Services (excludes Corporate & Other and eliminations). Operating_profit_share is normalized to the sum of operating gain for those three segments (excludes Corporate & Other).
Concession License
Legal
Concession License
Strength
Durability
Confidence
Evidence
BCBSA license agreements grant (largely) exclusive rights to use Blue Cross / Blue Shield names and marks in assigned territories.
Concession License moat: definition, examples, and stocks
Erosion risks
- BCBSA rule changes weakening exclusivity
- License termination from non-compliance or change-of-control constraints
- Antitrust/settlement changes enabling more second-bid competition for national accounts
Leading indicators
- BCBSA compliance status (e.g., 80% revenue under BCBS marks requirement)
- Material changes to BCBSA license terms or enforcement
- BCBS-related litigation/regulatory outcomes affecting territory rules
Counterarguments
- Exclusivity is not universal (some areas are non-exclusive)
- Large employers can still shop across carriers; brand does not guarantee lowest total cost
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Blue Cross / Blue Shield branding and reputation can improve win rates and retention in employer, individual, and government markets.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Negative publicity around insurers or prior authorization practices
- Service quality issues impacting member/employer perception
- Competitors increasing marketing spend and brand investment
Leading indicators
- Retention in key commercial books (ASO and fully insured)
- Customer complaint and regulator action trends
- Brand tracking/NPS where disclosed
Counterarguments
- Many buyers are price/network-driven and broker-mediated
- Brand may matter less in employer ASO where cost and admin fees dominate
CarelonRx
U.S. pharmacy benefit management and pharmacy services
2025 unaffiliated operating revenue: $24.483B (plus affiliated revenue $18.917B); operating gain: $2.418B. Revenue_share and operating_profit_share normalization: same approach as Health Benefits segment.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
PBM integrations (claims adjudication, drug data, member services) create operational switching costs for payers and employers.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Standardized APIs and data portability reduce integration frictions
- Clients carve out specialty pharmacy or point solutions
- New entrants offering tech-first PBM administration
Leading indicators
- Client churn / renewal rates
- Average implementation time for new clients
- Client satisfaction and service-level performance
Counterarguments
- PBM switching is common; large buyers may accept transition costs to reduce net cost
- Some PBM functionality is commoditized and interoperable
Suite Bundling
Demand
Suite Bundling
Strength
Durability
Confidence
Evidence
Distribution advantage from selling PBM services to Elevance-affiliated health plans plus external clients; supports cross-sell with medical and other Carelon services.
Suite Bundling moat: definition, examples, and stocks
Erosion risks
- Purchasers push for best-of-breed vendors and unbundle PBM
- Regulatory constraints on tying/bundling
- Competitors bundle PBM + medical + services at larger scale
Leading indicators
- Share of PBM business that is external vs affiliated
- Cross-sell attach rates to medical membership
- Pricing pressure in PBM RFPs
Counterarguments
- Some buyers avoid bundled arrangements for transparency and cost benchmarking
- Affiliated volume can be viewed as captive and does not guarantee external competitiveness
Carelon Services
U.S. healthcare services for payers and providers (care management, behavioral health, utilization management, care delivery)
2025 unaffiliated operating revenue: $7.141B (plus affiliated revenue $21.175B); operating gain: $0.960B. Revenue_share and operating_profit_share normalization: same approach as Health Benefits segment.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Care management, provider enablement, and utilization management workflows rely on data/analytics embedded in payer operations, raising switching costs.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Data sharing restrictions and privacy regulation
- Competitors with larger datasets and provider footprints
- Analytics tooling commoditization (AI/automation)
Leading indicators
- Contract renewal and retention rates for Carelon Services
- Operational KPIs: turnaround times, authorization accuracy, provider satisfaction
- Regulatory changes affecting data use (HIPAA/mental health parity, etc.)
Counterarguments
- Payers frequently run UM/care management in-house or switch vendors via RFP
- Switching costs may be moderate if processes are standardized
Evidence
Paraphrase: BCBSA license gives exclusive/non-exclusive use of BCBS names and marks by territory.
Supports the legal right-to-operate/brand licensing moat (territorial rights, compliance requirements, termination risk).
Paraphrase: company highlights capitalizing on Blue Cross brand strength in its markets.
Management explicitly frames the Blue brand as a strategic asset supporting competitive positioning.
Paraphrase: CarelonRx provides claims adjudication, a prescription drug database, and member services as part of its PBM stack.
These are embedded workflows/data systems that typically require material integration work to replace.
Paraphrase: CarelonRx markets pharmacy services to affiliated health plans and to customers outside Elevance-owned plans.
Indicates a built-in distribution channel (affiliated) plus external growth, enabling bundling/cross-sell.
Paraphrase: Carelon Services leverages data/insights for care management and provider enablement, including utilization management.
Supports the workflow/data integration mechanism behind switching costs.
Risks & Indicators
Erosion risks
- BCBSA rule changes weakening exclusivity
- License termination from non-compliance or change-of-control constraints
- Antitrust/settlement changes enabling more second-bid competition for national accounts
- Negative publicity around insurers or prior authorization practices
- Service quality issues impacting member/employer perception
- Competitors increasing marketing spend and brand investment
Leading indicators
- BCBSA compliance status (e.g., 80% revenue under BCBS marks requirement)
- Material changes to BCBSA license terms or enforcement
- BCBS-related litigation/regulatory outcomes affecting territory rules
- Retention in key commercial books (ASO and fully insured)
- Customer complaint and regulator action trends
- Brand tracking/NPS where disclosed
Research ELV elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.